Announcement PDF Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Presentation Materials – Shareholder Webinar on Licensing Agreement 02 July 2025 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to release the presentation slides accompanying today’s shareholder webinar, which will provide an update on the Company’s recent strategic milestone — the global license agreement with Elanco Animal Health. The presentation provides an overview of:     Overview of the Global Licensing Agreement with Elanco The significance of the agreement in accelerating regulatory and commercial readiness for NUZ-001 How this milestone strengthens Neurizon’s strategic position across clinical development, patient access, and manufacturing The Company’s forward strategy and key milestones Presentation slides are available as an attachment to this announcement. The recording of the presentation will be made available on Neurizon’s website at www.neurizon.com. -ENDSThis announcement has been authorized for release by the Board of Neurizon Therapeutics Limited. For further information, please contact: Dr. Michael Thurn Managing Director and Chief Execufive Officer Neurizon Therapeufics Limited enquiries@neurizon.com +61 (3) 9692 7222 Lidija Damjanovic Head of Markefing and Corporate Affairs Neurizon Therapeufics Limited lidija@neurizon.com +61 (0) 425 700 504 Released through: Henry Jordan, Six Degrees Investor Relations, +61 (0) 431 271 538 About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. Neurizon Investor Hub We encourage you to ufilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This plafform offers an opportunity to submit quesfions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit hftps://investorhub.neurizon.com Neurizon® is a registered trademark of Neurizon Therapeutics Limited Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Shaping the future of neurodegenerative diseases Elanco Licensing Agreement Webinar 02 July 2025 ASX: NUZ Disclaimer This disclaimer applies to this presentation and the information contained in it (This presentation has been prepared by Neurizon® Therapeutics Limited (ASX: NUZ) (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation. This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so). Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company. Future Matters This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. US Disclosure This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers. Neurizon® is a registered trademark of Neurizon Therapeutics Elanco Licensing Agreement Webinar, July 2025 2 Our vision is to lead the development of neurodegenerative treatments towards a promising new horizon for patients 3 Our mission is to advance innovative, disease-modifying therapies that address the underlying pathology and drivers of neurodegenerative conditions Our success is underpinned by a clear strategic focus on: Elanco Licensing Agreement Webinar, July 2025 4 NUZ-001: A Platform Molecule for Proteinopathy-Driven Diseases Impaired proteostasis contributes to intracellular inclusion bodies of misfolded proteins is a hallmark of neurodegenerative diseases TDP-43 Amyloid beta Tau alpha Synuclein mHTT ALS/AD/PD/FTD/CTE AD/PD AD/PD/FTD/CTE/PSP AD/PD HD NUZ-001 represents a mechanism-driven, disease-agnostic approach to treating neurodegeneration by rebalancing proteostasis and reversing core cellular dysfunction AD = Alzheimer’s Disease; ALS = Amyotrophic Lateral Sclerosis; CTE = Chronic Traumatic Encephalopathy; FTD = Frontotemporal Dementia; HD = Huntington Disease; PD = Parkinson’s Disease; PSP = Progressive Supranuclear Palsy Elanco Licensing Agreement Webinar, July 2025 5 Our Strategic Progress Our initial focus is on advancing clinical work on ALS, following acceptance into the HEALEY ALS Platform Trial Regulatory and Commercialisation Requirements for Realisation • Access to animal safety data and manufacturing data critical to • Access to manufacturing at scale critical to future support future trials and potential regulatory approvals commercialisation FDA Accelerated approval possible on Phase 2 data Elanco Licensing Agreement Webinar, July 2025 6 Global License with Elanco Exclusive global rights to Elanco’s data package and intellectual property LICENSE AGREEMENT SUPPLY AGREEMENT License Agreement: A foundational step in formalising Neurizon’s relationship with Elanco. Critical to future global regulatory approval and commercialization. Supply Agreement: Agreed and planned next step in further expanding formalisation of Neurizon’s relationship with Elanco. License: An exclusive global licensing agreement providing worldwide rights to utilise Elanco’s intellectual property for the treatment, palliation, prevention, or cure of neurodegenerative diseases in humans. Indicative Terms: Nominal upfront fee with additional approval and sale milestones1 and tiered single digit royalty on sales. Status: License Agreement outlines key terms for the conclusion of a Supply Agreement, including duration and price. Supply Agreement expected to be finalised prior to the end of CY2025. Expected Outcome: Supply Agreement expected to provide access to a long-term, scalable source of GMP-compliant monepantel, the active pharmaceutical ingredient in NUZ-001. Clear pathway for accelerated global commercialization and a de-risking of global regulatory approval 1 Refer to the ASX announcement dated 02 July 2025 Elanco Licensing Agreement Webinar, July 2025 7 Accelerated & Streamlined Path to NDA and Launch Elanco Licensing Agreement Module 1 Administrative Module 2 Summary Documents Fast Track Designation allows for rolling submission of completed modules Module 3 Quality Module 4 Non-Clinical Module 5 Clinical 01 Comprehensive non-clinical safety License Agreement package 02 Complete API GMP documentation of • Strengthens NDA readiness • Reduces development cost • Supports accelerated timeline & launch readiness the manufacturing process for the FDA 03 Improves alignment with FDA module expectations 04 De-risked regulatory approval process Elanco Licensing Agreement Webinar, July 2025 8 FDA Review Progressing Toward Clinical Hold Resolution: PK Studies in Progress / Complete Response on Track Regulatory Support PK Studies • • • • • The FDA continues to review our strategy to address the clinical hold​ Neurizon remains engaged and responsive to agency requests​ Two pharmacokinetic studies placed at leading CRO Studies ahead of schedule; treatment phase complete Study reports expected in July CY2025 Next Steps Momentum • • • Complete response package for clinical hold progressing as planned Clinical hold clearance expected following completion of PK studies Progressing startup activities towards HEALEY ALS Platform Trial inclusion and broader clinical advancement PK Studies Initiated PK Studies Completion FDA Submission & Hold Lift HEALEY Trial First Patient In Top Line Results Expected April CY2025 June CY2025 July/August CY2025 H2 CY2025 H1 CY2027 Note: Timelines indicative and subject to regulatory and operational variation Commercialisation Readiness CY2028 Elanco Licensing Agreement Webinar, July 2025 9 Investment credentials for NUZ-001 De-risked clinical program for a rare neurodegenerative disease positioned for near-term regulatory approval and launch Well-characterized Drug ✓ • Oral bioavailable • Crosses the Blood Brain Barrier • “Rediscovered” veterinary drug Restores Proteostasis ✓ ✓ • Promising Phase 1 data • Accepted into HEALEY ALS Platform Trial • Access to extensive data and IP • Supply Agreement Near-term Regulatory Strategy ✓ • Targets the underlying pathology – protein aggregation • Multiple indications possible Clinical POC Strategic Agreements • FDA accelerated approval possible • Multiple regulatory designations • High deal flow for neurology assets ✓ ✓ Strong IP Position • Patent protection out to 2039 • World class team assembled to maximise IP Elanco Licensing Agreement Webinar, July 2025 10 Thank You Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com